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ABSTRACT
Objectives: Anaemia has an adverse impact on the
outcome in the general patient population undergoing
percutaneous coronary intervention (PCI). The aim of
this study was to analyse the impact of anaemia on the
12-month clinical outcome of patients with atrial
fibrillation (AF) undergoing PCI and therefore requiring
intense antithrombotic treatment. We hypothesised that
anaemia might be associated with a worse outcome
and more bleeding in these anticoagulated patients.
Setting: Data were collected from 17 secondary care
centres in Europe.
Participants: Consecutive patients with AF
undergoing PCI were enrolled in the prospective,
multicenter AFCAS (Atrial Fibrillation undergoing
Coronary Artery Stenting) registry. Altogether, 929
patients participated in the study. Preprocedural
haemoglobin concentration was available for 861
(92.7%; 30% women). The only exclusion criteria were
inability or unwillingness to give informed consent.
Anaemia was defined as a haemoglobin concentration
of <12 g/dL for women and <13 g/dL for men.
Outcome measures: The primary endpoint was
occurrence of major adverse cardiac and
cerebrovascular events (MACCE) or bleeding events.
Results: 258/861 (30%) patients had anaemia.
Anaemic patients were older, more often had diabetes,
higher CHA2DS2-VASc scores, prior history of heart
failure, chronic renal impairment and acute coronary
syndrome. Anaemic patients had more MACCE than
non-anaemic (29.1% vs 19.4%, respectively, p=0.002),
and minor bleeding events (7.0% vs 3.3%,
respectively, p=0.028), with a trend towards more total
bleeding events (25.2% vs 21.7%, respectively,
p=0.059). No difference was observed in
antithrombotic regimens at discharge. In multivariate
analysis, anaemia was an independent predictor of
all-cause mortality at 12-month follow-up (hazard ratio
1.62, 95% CI 1.05 to 2.51, p=0.029).
Conclusions: Anaemia was a frequent finding in
patients with AF referred for PCI. Anaemic patients had
a higher all-cause mortality, more thrombotic events
and minor bleeding events. Anaemia seems to be an
identification of patients at risk for cardiovascular
events and death.
Trial registration: ClinicalTrials.gov number
NCT00596570.
INTRODUCTION
It is estimated that around 5% of patients
undergoing percutaneous coronary interven-
tion (PCI) need long-term oral anticoagulation
(OAC) due to atrial fibrillation (AF).1 2 Yet, the
current recommendations on the management
Strengths and limitations of this study
▪ The enrolment of consecutive patients with the
only exclusion criteria being unwillingness/inabil-
ity to participate in the study. In this sense, the
study population represents well real-world
patients with AF referred for PCI.
▪ The study adds to our knowledge on the preva-
lence and impact of anaemia in patients with AF
undergoing PCI and thus requiring combination
antithrombotic medication. It shows that
anaemia is a frequent finding and that even mild
anaemia has an adverse impact on outcome.
▪ The current study has the inherent limitations of
the observational study design, including individ-
ual risk-based decision-making in treatment
choices, which may introduce selection bias.
Another possible confounder is the heterogeneity
of the AF population among the participating
centres and some differences in the periproce-
dural routines.
▪ The aetiology of anaemia could not be systemat-
ically investigated and is therefore outside the
scope of this study.
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of antithrombotic treatment in patients with AF undergo-
ing PCI and stenting are mainly derived from small studies,
amounting to a weak level of evidence.3 4 Moreover, the
real-world management of patients on OAC undergoing
PCI is variable, and only partially adherent to the current
recommendations.5
Defined according to the WHO, anaemia has been
reported to affect nearly 25% of patients undergoing
PCI and stenting. Anaemic patients undergoing PCI are
generally older, with more comorbidities, and have
higher rates of in-hospital mortality and major adverse
cardiac and cerebrovascular events (MACCE), as well as
1-year mortality.6 7 Furthermore, low admission haemo-
globin level was found to be an independent predictor
of in-hospital and long-term mortality, and was asso-
ciated with higher rates of in-hospital minor and major
bleeding events in patients undergoing primary PCI for
ST-segment elevation myocardial infarction (MI).8 9
However, little is known about the effect of anaemia
on the outcome of patients with AF undergoing PCI,
and thus requiring intensive antithrombotic treatment.
Anaemia is possibly a marker of high bleeding risk,
which could be aggravated by the underlying cause.
Therefore, we analysed data from the prospective
AFCAS (Atrial Fibrillation undergoing Coronary Artery
Stenting) registry to explore the impact of anaemia on




The AFCAS registry (ClinicalTrials.gov number
NCT00596570) is a prospective, multicenter registry that
enrolled patients with AF referred for PCI in five
European countries. The study design has been
described in detail previously.11 Patients were enrolled if
they had: (1) history of AF (paroxysmal, persistent or
permanent) or (2) ongoing AF during the index PCI.
Of the 929 participants, 861 (92.7%) had a preproce-
dural haemoglobin count available and were included in
this analysis.
Coronary angiography and PCI were performed via
either radial or femoral access, and haemostasis was
achieved according to local practice. Coronary lesions
were treated according to contemporary interventional
techniques. Low-molecular-weight heparin (enoxaparin
sodium, dalteparin), unfractionated heparin, bivalirudin
and glycoprotein IIb/IIIa inhibitors were administered at
the operator’s discretion. The postdischarge medication
was completely at the discretion of the treating physician.
The primary endpoints of the current study were
(1) occurrence of MACCE defined as a composite of all-
cause mortality, any non-fatal MI, any revascularisation,
definite/probable stent thrombosis, transient ischaemic
attack (TIA) or stroke and peripheral arterial embolism;
(2) bleeding events and (3) total adverse events
(a composite of MACCE plus bleeding events). Bleeding
events were defined according to the Bleeding
Academic Research Consortium (BARC) criteria as
minor (BARC 2) and major (BARC 3a, 3b, 3c and 5)
bleeding events; however, coronary artery bypass grafting
(CABG)-related bleeding was excluded12 (see online
table S1).
Anaemia was defined as a haemoglobin concentration
of <12 g/dL for women and <13 g/dL for men, accord-
ing to the definition of the WHO.13 Chronic renal
impairment was defined by an estimated glomerular fil-
tration rate below 60 mL/min.
Ethical aspects
The study was initiated by the investigators and con-
ducted according to the ethical guidelines of the 1964
Declaration of Helsinki, as revised in 2002. Informed
written consent was obtained from every patient after
full explanation of the study protocol. The study proto-
col was approved by the ethics committees of the partici-
pating centres.
Statistical analysis
For analysis, patients with available preprocedural meas-
urement of haemoglobin concentration were divided
into two subgroups: anaemic patients and control
patients without anaemia. Continuous variables were
reported as the mean±SD if normally distributed and as
median (IQR) if they were skewed. Data were tested for
normal distribution using the Kolmogorov-Smirnov and
Shapiro-Wilk tests. Categorical variables were described
with absolute and relative (percentage) frequencies.
Comparisons between the two study subgroups were per-
formed using the unpaired t test or Mann-Whitney
U test for continuous variables and Pearson χ2 or
Fisher’s exact test for categorical variables, as appropri-
ate. The Cox regression hazard model was used to iden-
tify the independent predictors of MACCE and all-cause
mortality at 12-month follow-up. Baseline variables cor-
relating at p<0.10 level with the dependent variable in
univariate analyses were entered in the Cox regression
model as covariates. The Cox regression hazard model
was used to identify the independent predictors of
MACCE and all-cause mortality at 12-month follow-up in
the subgroup of anaemic patients. Finally, we con-
structed Kaplan-Meier survival curves to display the
time-to-event relationship for the occurrence of all-cause
mortality, MACCE and all bleeding events. Statistical ana-
lysis was performed using SPSS statistical software (SPSS
V. 16.0.1, SPSS Inc, Chicago, Illinois, USA).
RESULTS
Baseline characteristics
Of the 929 patients enrolled in the AFCAS registry and
followed up for 12 months, 861 (92.7%) had available
preprocedural measurement of haemoglobin concentra-
tion, of whom 258 (30%) had anaemia and 603 (70%)
had normal haemoglobin concentration. Anaemic
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patients were older; more likely to have diabetes melli-
tus, hypertension, history of heart failure and chronic
renal impairment; HAS-BLED score ≥3; higher
CHA2DS2-VASc score and more likely presented with
acute coronary syndrome (ACS) as opposed to chronic
stable angina, compared with those without anaemia
(p<0.05 for all), as shown in table 1. Furthermore,
anaemic patients had more vessels treated during the
index procedure and a greater total stent length, com-
pared with those without anaemia (p<0.05 for both;
table 2). At discharge, no significant differences were
seen in the prescription of antithrombotic medications
in the two study groups (p=0.15; table 3). The duration
of clopidogrel treatment did not differ in anaemic
versus non-anaemic patients on triple therapy (median
(IQR): 3 (11) vs 3 (5) months, p=0.61), on dual antipla-
telet therapy (median (IQR): 12 (11) vs 12 (11) months,
p=0.72) or on vitamin K antagonist+clopidogrel (median
(IQR): 12 (11) vs 3 (11) months, p=0.65). Proton pump
inhibitors were more frequently prescribed to patients
with anaemia versus those without (47.7 vs 31.3%,
respectively, p<0.001).
Clinical outcome
Clinical outcomes at 12-month follow-up are presented
in table 4 and figure 1. The primary endpoint of
MACCE was significantly more frequent in anaemic
patients than those without anaemia (29.1 vs 19.4%,
respectively, p=0.002). This difference was driven by
higher rates of all-cause mortality, non-fatal MI and def-
inite/probable ST (p<0.05 for all). Anaemic patients
had more BARC 3a bleeding events (7.0% vs 3.3%,
respectively, p=0.028). No difference was seen in BARC 5
bleedings. There was a trend towards more total bleed-
ing events (25.2% in anaemic vs 21.7% in controls,
p=0.059; for detailed information on bleeding events see
see online table S2). Total adverse events occurred more
frequently in anaemic versus non-anaemic patients (43%
vs 31.5%, respectively, p=0.001).
The incidence of definite/probable stent thrombosis was
significantly higher in anaemic versus non-anaemic
patients (3.9% vs 0.7%, respectively, p=0.002). Patients who
developed stent thrombosis more often presented with
ACS than those who did not (80.0% vs 56.6%, respectively,
p=0.07); however, the use of triple therapy did not differ
statistically between groups (60.0% vs 73.3%, respectively,
p=0.25). Overall, nearly half (46.7%) of STevents occurred
early (<30 days). Acute (<24 h after index PCI), early
(<30 days) and late ST (>30 and <365 days) were detected
in 1 (0.4%) vs 1 (0.2%; p=0.51); 4 (1.6%) vs 2 (0.3%;
p=0.07) and 6 (2.3%) vs 2 (0.3%; p=0.01) in patients with
anaemia versus those without anaemia, respectively.
Table 1 Baseline clinical characteristics of the two study subgroups
Variable Anaemia (N=258) Non-anaemic (N=603) p Value
Age (years) 76 [9] 73 [11] <0.001
Female gender 89 (34.5) 170 (28.2) 0.074
Diabetes mellitus 119 (46.1) 191 (31.7) <0.001
Hypercholesterolaemia 162 (62.8) 407 (67.5) 0.183
Current or ex-smoking 26 (10.1) 62 (10.3) 1.00
Hypertension 221 (85.7) 503 (83.4) 0.48
Paroxysmal atrial fibrillation 103 (39.9) 229 (38.0) 0.594
Persistent atrial fibrillation 22 (8.5) 78 (12.9) 0.081
Permanent atrial fibrillation 129 (50) 294 (48.8) 0.766
CHA2DS2-VASc score >4 148 (57.4) 235 (39.0) <0.001
HAS-BLED score ≥3 215 (83.3) 441 (73.1) 0.001
History of peptic ulcer 17 (6.6) 27 (4.5) 0.236
History of cerebral haemorrhage 4 (1.6) 6 (1.0) 0.497
History of GI haemorrhage 9 (3.5) 12 (2.0) 0.144
History of heart failure 69 (26.7) 113 (18.7) 0.011
eGFR below 60 mL/min 119 (52.2) 175 (31.9) <0.001
Prior transient ischaemic attacks 12 (4.7) 30 (5.0) 1.00
Prior stroke 36 (14.0) 67 (11.1) 0.252
Prior MI 76 (29.5) 146 (24.2) 0.126
Prior PCI 47 (18.2) 100 (16.6) 0.555
Prior coronary bypass surgery 47 (18.2) 78 (12.9) 0.057
Proton pump inhibitors 123 (47.7) 189 (31.3) <0.001
Stable angina pectoris 81 (31.4) 289 (48.0) <0.001
ACS 177 (68.6) 313 (52.0) <0.001
Unstable angina pectoris 53 (20.5) 107 (17.7) 0.34
Non-ST-elevation MI 83 (32.2) 132 (21.9) 0.002
ST-elevation MI 41 (15.9) 74 (12.3) 0.156
Continuous variables are presented as median [IQR], whereas categorical variables are presented as frequency (percentage).
ACS, acute coronary syndrome; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; MI, myocardial infarction; PCI, percutaneous
coronary intervention.
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In univariate analysis, age above 75, diabetes, congest-
ive heart failure, anaemia, chronic renal impairment,
ACS at presentation and total stent length were strongly
correlated with MACCE and all-cause mortality at
12-month follow-up. In the Cox regression model,
including all the above variables, independent predic-
tors of all-cause mortality were anaemia (hazard ratio
(HR) 1.62, 95% CI 1.05 to 2.51, p=0.029), ACS at pres-
entation (HR 2.26, 95% CI 1.37 to 3.75, p=0.001),
chronic renal impairment (HR 2.35, 95% CI 1.52 to
3.65, p<0.001) and diabetes (HR 1.76, 95% CI 1.15 to
2.70, p=0.009). In contrast, anaemia as a categorical vari-
able was not an independent predictor of MACCE at
12-month follow-up, unlike age above 75 years (HR 1.7,
95% CI 1.2 to 2.4, p=0.004), diabetes (HR 1.7, 95% CI
1.2 to 2.3, p=0.002), ACS at presentation (HR 1.7, 95%
CI 1.2 to 2.3, p=0.003) and congestive heart failure (HR
1.5, 95% CI 1.0 to 2.1, p=0.03).
We performed the multivariate model also using
haemoglobin as a continuous variable. Independent pre-
dictors of all-cause mortality were preprocedural haemo-
globin (HR 0.82, 95% CI 0.72 to 0.93, p=0.002), ACS at
presentation (HR 2.07, 95% CI 1.25 to 3.45, p=0.005),
chronic renal impairment (HR 2.06, 95% CI 1.31 to
3.24, p=0.002) and diabetes (HR 1.75, 95% CI 1.14 to
2.70, p=0.01) in a Cox regression model including age
over 75 years, total stent length and number of treated
vessels as covariates. On the contrary to what was found
when assessing anaemia as a categorical variable, haemo-
globin as a continuous variable also predicted MACCE.
Independent predictors of MACCE were preprocedural
haemoglobin (HR 0.89, 95% CI 0.81 to 0.98, p=0.016),
ACS at presentation (HR 1.55, 95% CI 1.10 to 2.18,
p=0.012), congestive heart failure (HR 1.45, 95% CI 1.03
to 2.04, p=0.035), age over 75 years (HR 1.77, 95% CI
1.27 to 2.45, p=0.001) and diabetes (HR 1.55, 95% CI
1.13 to 2.13, p=0.007) in a Cox regression model includ-
ing also total stent length, chronic renal impairment
and number of treated vessels as covariates.
When the anaemic patients were analysed separately
in the Cox regression model, age over 75 years and ACS
at presentation were identified as independent predic-
tors of MACCE at 12 months, and chronic renal impair-
ment, age over 75 years and ACS at presentation as
independent predictors of all-cause mortality.
Among 861 patients with available preprocedural
measurement of haemoglobin concentration, 26 (2.8%)
had severe anaemia (defined as haemoglobin below
10 g/dL). In this subgroup, MACCE occurred in 12
(46.2%) patients, 10 (38.5%) patients died and 8
(30.8%) experienced a BARC 2–5 bleeding episode.
At discharge, triple therapy was prescribed in 18
(69.2%) patients, dual antiplatelet therapy in 8 (30.8%)
and no patient was prescribed vitamin K antagonists plus
a single antiplatelet drug. Proton pump inhibitors were
prescribed at discharge in 18 (69.2%) patients, and 1
(3.8%) patient had a history of gastrointestinal bleeding.
DISCUSSION
Our study is the first report on the impact of anaemia
on the long-term clinical outcome of patients with AF
undergoing PCI. The AFCAS registry represents a
real-life cohort of high-risk patients with AF requiring
PCI. The results of the current study showing that 30%
Table 2 Procedural data of the two study subgroups
Variable Anaemia (N=258) Non-anaemic (N=603) p Value
Femoral access 196 (76.0) 435 (72.1) 0.275
Number of treated vessels 1.22±0.45 1.15±0.41 0.04
DES 67 (27.0) 138 (23.6) 0.293
Periprocedural INR 1.9 [1] 1.88 [1] 0.509
Stent diameter (mm) 3 [1] 3 [1] 0.965
Total stent length (mm) 20 [18] 19 [14] 0.014
Procedural success 252 (97.7) 582 (96.5) 0.085
Haemostasis
Manual compression 112 (43.4) 249 (41.3) 0.765
Compression device* 49 (19.0) 155 (25.7) 0.083
Access-site closure device† 82 (31.8) 165 (27.4) 0.154
Continuous variables are presented as mean±SD or median [IQR], whereas categorical variables are presented as frequency (percentage).
*FemoStop, pneumatic compression device (Radi medical system, Sweden).
†Angioseal, closure device (St Jude medical, USA).
DES, drug-eluting stents; INR, International Normalised Ratio.
Table 3 Prescription of antithrombotic medications at






Triple therapy 181 (70.2) 442 (73.3) 0.15
DAPT 58 (22.5) 100 (16.6)
VKA plus
clopidogrel
15 (5.8) 51 (8.5)
VKA plus aspirin 4 (1.6) 10 (1.7)
Variables are presented as frequency (percentage).
DAPT, dual antiplatelet therapy; VKA, vitamin K antagonist.
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of the patients were anaemic confirm the previous
reports that anaemia is a frequent finding in real-world
patients with AF referred for PCI.6–9 14 Anaemic patients
in the AFCAS registry were older, with more comorbid-
ities and presented more often with ACS, compared with
non-anaemic patients, as also reported in previous
cohorts.6 7 9 14
Overall, the 12-month clinical outcome was worse in
anaemic patients. Anemia remained an independent
predictor of all-cause mortality in multivariate analysis.
The higher rate of all-cause mortality might be related
to the higher risk profile in anaemic patients, as well as
the underlying disease causing anaemia. Furthermore,
anaemic patients had more frequent MACCE at
12 months, primarily driven by higher rates of all-cause
mortality, and non-fatal MI. However, anaemia was not
an independent predictor of MACCE. The higher rate
of non-fatal MI might be explained, at least in part, by
the higher frequency of ACS at presentation in anaemic
patients.
The estimated thromboembolic risk of anaemic
patients according to CHADS2 score was higher.
However, no excess in TIA or stroke was seen during the
follow-up and only a trend towards more bleeding was
observed. This is contradictory to previous studies which
have reported a higher incidence of cardiac and cere-
brovascular thrombotic events at long-term follow-up in
anaemic versus non-anaemic patients in various patient
cohorts referred for PCI.7 9 14–18 The relatively small
number of complications in our patient cohort might
explain this difference.
The estimated bleeding risk according to the
HAS-BLED score was higher in anaemic patients, but
there was only a trend towards increased risk of major
bleeding. However, the results of the current study
support the previous reports on the increased bleeding
risk associated with anaemia in various patient groups
undergoing PCI.8 9 19 Anaemia may be a marker and
consequence of an underlying condition such as bleed-
ing diathesis, occult gastrointestinal bleeding or malig-
nancy that augments the bleeding risk. An interesting
observation is that neither the presence of anaemia nor
higher estimated bleeding risk seemed to affect the clini-
cian’s choice of antithrombotic medications at dis-
charge. In view of our results, patients with anaemia
tolerated triple therapy surprisingly well with only a
trend towards increased bleeding.
We observed that the rate of definite or probable stent
thrombosis was significantly higher in anaemic versus
non-anaemic patients (p=0.002). ACS at presentation
may have contributed to the higher rate of stent throm-
bosis in anaemic patients, as patients with anaemia more
often presented with ACS versus those without anaemia.
In addition, in individual cases, the presence of anaemia
may have influenced the choice of antithrombotic medi-
cation. Also, a bleeding event could have led to interrup-
tion of combination antithrombotic therapy, and thus to
a higher risk of stent thrombosis. Consistent with our
results, Pilgrim et al14 observed a higher rate of definite
stent thrombosis at 4-year follow-up in anaemic patients
who underwent PCI with unrestricted use of
drug-eluting stents, compared with non-anaemic ones.
Interestingly, in a recent study, anaemia was the only
independent predictor of high residual platelet reactivity
on clopidogrel in a series of patients undergoing PCI.20
These observations warrant further studies to clarify the
underlying mechanisms.
The effect of anaemia on the clinical outcome of PCI
appears early during hospitalisation. Kaplan-Meier event-
free survival curves in the current study revealed that
Table 4 Clinical outcome at 12-month follow-up in the two study subgroups
Endpoints Anaemia (N=258) Non-anaemic (N=603) p Value
MACCE 75 (29.1) 117 (19.4) 0.002
All-cause mortality 48 (18.6) 50 (8.3) <0.001
Stroke/TIA 6 (2.3) 17 (2.8) 0.819
Peripheral arterial embolism 2 (0.8) 5 (0.8) 1.00
Non-fatal myocardial infarction 24 (9.3) 27 (4.5) 0.011
Any revascularisation 19 (7.4) 51 (8.5) 0.683
Definite/probable stent thrombosis 10 (3.9) 4 (0.7) 0.002
Total bleeding events 65 (25.2) 131 (21.7) 0.059
Minor bleeding (BARC 2) 22 (8.5) 48 (8.0) 0.786
Major bleeding (BARC 3a, 3b, 3c, 5) 33 (12.8) 56 (9.3) 0.142
Access site complications 25 (9.7) 49 (8.1) 0.51
Pseudoaneurysm 7 (2.7) 18 (3.0) 1.0
Red blood cell transfusion 10 (3.9) 5 (0.9) 0.002
Need for corrective surgery 5 (1.9) 8 (1.3) 0.25
Prolonged hospitalisation 15 (5.8) 23 (3.8) 0.21
Total adverse events 111 (43.0) 190 (31.5) 0.001
Variables are presented as frequency (percentage).
BARC, Bleeding Academic Research Consortium; MACCE, major adverse cardiac and cerebrovascular events; TIA, transient ischaemic
attacks.
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most of the thrombotic as well as bleeding events
occurred early (within 30 days) following the index PCI
(figure 1). This finding is in line with previous
reports.6 8 9 15 In patients with coronary artery disease,
anaemia may aggravate myocardial ischaemia and unveil
significant coronary obstruction. Cardiac output
increases in patients with anaemia in order to maintain
adequate oxygen delivery to the tissues. This increases
heart rate and induces myocardial hypertrophy, which in
turn increases myocardial oxygen demand, and further
exaggerates the myocardial oxygen demand/supply
imbalance.21 On the other hand, patients with severe
anaemia receive more frequent blood transfusion, which
was reported to have an adverse impact on survival after
PCI.22 Unfortunately, information on blood transfusions
was not available in our registry except for the
in-hospital phase. More importantly, anaemia is fre-
quently associated with severe underlying chronic dis-
eases which may compromise long-term survival. Of
note is a recent report suggesting that in patients who
underwent PCI with drug-eluting stents, those in whom
anaemia improved at follow-up had less MACCE at a
median follow-up of 25 months, compared with those
with sustained anaemia, suggesting that a transient cause
is less detrimental than a long-standing state causing
anaemia, for example, malignancy.16
Limitations of the study
The current study has the inherent limitations of the
observational study design, including individual risk-
based decision-making in treatment choices, which may
introduce selection bias, even though we did not
observe any difference between the two study groups in
the antithrombotic treatment prescribed at discharge.
Another possible confounder is the heterogeneity of the
AF population among the participating centres and
some differences in the periprocedural routines.
Moreover, the aetiology of anaemia was not systematic-
ally investigated; yet, it is beyond the scope of the
current study. The strength of the study is the enrolment
of consecutive patients with the only exclusion criteria
being unwillingness/inability to participate in the study.
Figure 1 Kaplan-Meier survival curves for the occurrence of adverse events in anaemic (dotted lines) versus non-anaemic
(solid line) patients at 2-month follow-up: all-cause mortality (A), MACCE free survival (B) and bleeding event-free survival (C).
MACCE, major adverse cardiac and cerebrovascular events; PCI, percutaneous coronary intervention.
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In this sense, the study population represents well real-
world patients with AF referred for PCI.
CONCLUSION
Anaemia was a frequent finding in patients with AF
referred for PCI. Anaemia seems to be an independent
risk factor for all-cause mortality during 12-month
follow-up. Anaemia is also associated with more MACCE
and a trend towards a higher rate of bleeding.
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